Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders
申请人:Kranich Remo
公开号:US20080249107A1
公开(公告)日:2008-10-09
Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine
wherein the symbols, indices and substituents have the following meaning
R
1
═H, CN, NO
2
, CF
3
, F, Cl, Br, I, CH
3
R
2
═H, CN, NO
2
, CF
3
, F, Cl, Br, I, CH
3
, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl and
either R
1
or R
2
must be H
R
3
═H, CN, NO
2
, CF
3
, F, Cl, Br, I, CH
3
, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl
then X is e.g.
with R
4
being H, CH
3
, CH
2
CH
3
or
and Y being
or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.
含有式(Ia)或(Ib)中至少一种化合物和药学上可接受的载体的制药组合物,在医学上有用。其中符号、指数和取代基的含义如下:
R1═H、CN、NO2、CF3、F、Cl、Br、I、CH3
R2═H、CN、NO2、CF3、F、Cl、Br、I、CH3、Et、n-Pr、i-Pr、n-Bu、t-Bu、苯基、噻吩基、呋喃基、噻唑基,且R1或R2中必须有一个为H
R3═H、CN、NO2、CF3、F、Cl、Br、I、CH3、Et、n-Pr、i-Pr、n-Bu、t-Bu、苯基、噻吩基、呋喃基、噻唑基
然后X为例如,R4为H、CH3、CH2CH3或,Y为或上述式(Ia)或(Ib)中识别的化合物的药学上可接受的盐、酯或酰胺以及前药。这些化合物被应用于调节由E、P或L选择素结合介导的体内和体外结合过程。